Asymchem Laboratories Tian Jin Co Ltd Asset Resilience Ratio
Asymchem Laboratories Tian Jin Co Ltd asset resilience ratio. Asymchem Laboratories Tian Jin Co Ltd (002821) has an Asset Resilience Ratio of 5.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 002821 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Asymchem Laboratories Tian Jin Co Ltd (2013–2025)
Asset resilience ratio of Asymchem Laboratories Tian Jin Co Ltd from 2013 to 2025. This chart shows how Asymchem Laboratories Tian Jin Co Ltd's Asset Resilience Ratio has changed over time. See 002821 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Asymchem Laboratories Tian Jin Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Asymchem Laboratories Tian Jin Co Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.05 Billion | 5.07% |
| Total Liquid Assets | CN¥1.05 Billion | 5.07% |
Asset Resilience Insights
- Limited Liquidity: Asymchem Laboratories Tian Jin Co Ltd maintains only 5.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Asymchem Laboratories Tian Jin Co Ltd Industry Peers by Asset Resilience Ratio
Compare Asymchem Laboratories Tian Jin Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.57% |
|
Eupraxia Pharmaceuticals Inc
TO:EPRX |
Biotechnology | 25.13% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Asymchem Laboratories Tian Jin Co Ltd Asset Resilience Ratio by Year (2013–2025)
Asymchem Laboratories Tian Jin Co Ltd asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Asymchem Laboratories Tian Jin Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.51% | CN¥1.12 Billion ≈ $163.39 Million |
CN¥20.28 Billion ≈ $2.97 Billion |
-2.48pp |
| 2024-12-31 | 7.98% | CN¥1.54 Billion ≈ $225.32 Million |
CN¥19.29 Billion ≈ $2.82 Billion |
-1.66pp |
| 2023-12-31 | 9.64% | CN¥1.91 Billion ≈ $278.88 Million |
CN¥19.77 Billion ≈ $2.89 Billion |
-2.15pp |
| 2022-12-31 | 11.79% | CN¥2.15 Billion ≈ $314.77 Million |
CN¥18.24 Billion ≈ $2.67 Billion |
+9.15pp |
| 2021-12-31 | 2.65% | CN¥401.20 Million ≈ $58.71 Million |
CN¥15.16 Billion ≈ $2.22 Billion |
+2.42pp |
| 2018-12-31 | 0.22% | CN¥7.11 Million ≈ $1.04 Million |
CN¥3.19 Billion ≈ $466.12 Million |
-2.06pp |
| 2015-12-31 | 2.28% | CN¥29.01 Million ≈ $4.25 Million |
CN¥1.27 Billion ≈ $186.06 Million |
+2.27pp |
| 2014-12-31 | 0.01% | CN¥88.56K ≈ $12.96K |
CN¥1.06 Billion ≈ $154.84 Million |
-0.05pp |
| 2013-12-31 | 0.06% | CN¥502.60K ≈ $73.55K |
CN¥913.19 Million ≈ $133.63 Million |
-- |
About Asymchem Laboratories Tian Jin Co Ltd
Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, incl… Read more